The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Smart Nanocarriers as an Emerging Platform for Cancer Therapy: A Review
Open accessAbstract
Cancer is a group of disorders characterized by uncontrolled cell growth that affects around 11 million people each year globally. Nanocarrier-based systems are extensively used in cancer imaging, diagnostics as well as therapeutics; owing to their promising features and potential to augment therapeutic efficacy. The focal point of research remains to develop new-fangled smart nanocarriers that can selectively respond to cancer-specific conditions and deliver medications to target cells efficiently. Nanocarriers deliver loaded therapeutic cargos to the tumour site either in a passive or active mode, with the least drug elimination from the drug delivery systems. This review chiefly focuses on current advances allied to smart nanocarriers such as dendrimers, liposomes, mesoporous silica nanoparticles, quantum dots, micelles, superparamagnetic iron-oxide nanoparticles, gold nanoparticles and carbon nanotubes, to list a few. Exhaustive discussion on crucial topics like drug targeting, surface decorated smart-nanocarriers and stimuli-responsive cancer nanotherapeutics responding to temperature, enzyme, pH and redox stimuli have been covered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002 · cited 1×
“Interstitial fluid pressure (IFP) is one obstacle to the efficient deposition of drug-incorporated nanocarriers in cancer cells [15].”
BackgroundCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Exploiting the enhanced permeability and retention effect for tumor targeting
Iyer, A. K., Khaled, G., Fang, J., & Maeda, H. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.07.005 · Cited by 1,846 · cited 1×
“Successful nanocarrier advancements can overcome various biological obstacles, such as IFP (interfacial fluid pressure) and RES (reticuloendothelial tissues) [16].”
BackgroundGold Nanoparticles in Diagnostics and Therapeutics for Human Cancer
Singh, P., Pandit, S., Mokkapati, V. R. S. S., Garg, A., Ravikumar, V., & Mijakovic, I. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071979 · Cited by 1,038
Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review
Kanamala, M., Wilson, W. R., Yang, M., Palmer, B. D., & Wu, Z. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.061 · Cited by 1,004
Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review
Hossen, S., Hossain, M. K., Basher, M. K., Mia, M. N. H., Rahman, M. T., & Uddin, M. J. (2019) · Journal of Advanced Research · doi:10.1016/j.jare.2018.06.005 · Cited by 998 · cited 7×
“Aptamers, transferrin, peptides, folate and antibodies are the most commonly studied ligands [3].”
BackgroundInfluentialInternal stimuli-responsive nanocarriers for drug delivery: Design strategies and applications
Liu, M., Du, H., Zhang, W., & Zhai, G. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.11.030 · Cited by 235 · cited 1×
“The following are detailed information on the many types of endogenous stimuli [140].”
BackgroundOxime Linkage: A Robust Tool for the Design of pH-Sensitive Polymeric Drug Carriers
Jin, Y., Song, L., Su, Y., Zhu, L., Pang, Y., Qiu, F., Tong, G., Yan, D., Zhu, B., & Zhu, X. (2011) · Biomacromolecules · doi:10.1021/bm200956u · Cited by 216
Wan, X., Beaudoin, J. J., Vinod, N., Min, Y., Makita, N., Bludau, H., Jordan, R., Wang, A., Sokolsky, M., & Kabanov, A. V. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.032 · Cited by 201 · cited 1×
“conducted a study of designer polymeric micelles for targeting ovarian and breast cancers, which featured simultaneous loading of paclitaxel and cisplatin in amphiphilic copolymer-based micelles, which resulted in a considerable increase in loading efficiencies [60].”
BackgroundFunctionalized carbon nanotubes for anticancer drug delivery
Lay, C. L., Liu, J., & Liu, Y. (2011) · Expert Review of Medical Devices · doi:10.1586/erd.11.34 · Cited by 71
Decision-making in priority setting for medicines—A review of empirical studies
Vuorenkoski, L., Toiviainen, H., & Hemminki, E. (2008) · Health Policy · doi:10.1016/j.healthpol.2007.09.007 · Cited by 62 · cited 1×
“However, novel approaches that contain growing healthcare costs simultaneously maintaining clinical efficacy, seem to be almost inevitable [197].”
Background
Cited by
Chehelgerdi, M., Chehelgerdi, M., Allela, O. Q. B., Pecho, R. D. C., Jayasankar, N., Rao, D. P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01865-0 · Cited by 1,062
Sakore, P., Bhattacharya, S., Belemkar, S., Prajapati, B. G., & Elossaily, G. M. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2023.101264 · Cited by 64
Sharma, S., Bhattacharya, S., Joshi, K., & Singh, S. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05331-8 · Cited by 13
Bhirud, D., Bhattacharya, S., & Prajapati, B. G. (2024) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37732 · Cited by 7
Metadata
- Authors
- Kenchegowda, M., Rahamathulla, M., Hani, U., Begum, M. Y., Guruswamy, S., Osmani, R. A. M., Gowrav, M. P., Alshehri, S., Ghoneim, M. M., Alshlowi, A., & Gowda, D. V.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2021-12-27
- Volume
- 27
- Issue
- 1
- Pages
- 146
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W4200154441
- Cited by
- 167
- References
- 11
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.